Complete List of BRAF inhibitor Medicines
Brand: TAFINLAR |
Strength: 10 mg |
Form: Dispersible Tablet for Oral Suspension
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; used in combination with trametinib for BRAF V600E or V600K mutation-positive meta...
Brand: TAFINLAR |
Strength: 50 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; also indicated for non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
...
Brand: TAFINLAR |
Strength: 75 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; used in combination with trametinib for the treatment of BRAF V600E or V600K mutat...
Brand: TAFINLAR |
Strength: 75 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; also indicated for the treatment of non-small cell lung cancer (NSCLC) with BRAF V...
Brand: TAFINLAR |
Strength: 50 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as well as for the treatment of non-small cell lun...
Brand: TAFINLAR |
Strength: 50 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; also used in combination with trametinib for the treatment of BR...
Brand: TAFINLAR |
Strength: 50 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as well as for the treatment of non-small cell lu...
Brand: TAFINLAR |
Strength: 75 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and for the treatment of patients with non-small c...
Brand: BRAFTOVI |
Strength: 50 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations; used in combination with binimetinib for the treatment of BRAF V600E or V600K muta...
Brand: BRAFTOVI |
Strength: 75 mg |
Form: Capsules
Class: | BRAF inhibitor
Use: | Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with binimetinib; also used for other BRAF V60...
Brand: BRAFTOVI |
Strength: 75 mg |
Form: Hard Gelatin Capsules
Class: | BRAF inhibitor
Use: | Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation; used in combination with binimetinib for the treatment of BRA...
Brand: BRAFTOVI |
Strength: 75 mg |
Form: Capsules
Class: | BRAF kinase inhibitor
Use: | Encorafenib (BRAFTOVI) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a...
Brand: ZELBORAF |
Strength: 240 mg |
Form: Tablets
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E mutation
Adult dose: | 960 mg orally twice daily (240 mg tablets, taken as four tablets)
Pediatric...
Brand: ZELBORAF |
Strength: 240 mg |
Form: Tablets
Class: | BRAF inhibitor
Use: | Treatment of unresectable or metastatic melanoma with BRAF V600E mutation
Adult dose: | 960 mg orally twice daily (240 mg tablets taken as 4 tablets)
Pediatric dos...